当地时间2023年6月12日，三优生物医药（上海）有限公司正式宣布，“三优超万亿共同轻链抗体发现平台”隆重上线。
共同轻链抗体发现平台是三优生物九大万亿级抗体发现平台之一，库容高达1.12E+12 CFU。针对单一靶点，该平台可筛选出数百个分子序列差异大的先导分子，进一步组装后，可获得成药性良好的双抗，这为获得构型与经典天然单克隆抗体相似的构型，却有双特异性的双抗提供了基础。
双抗药物的开发正处于抗体研发浪潮的前端，与单克隆抗体相比，双抗增加了一个特异性抗原结合位点，为抗体带来了更强的特异性和更好的靶向性。截至2023年3月，全球有436项双抗药物处于临床试验阶段，并已有10款双抗药物获批上市，销售额超过50亿美元。
三优生物共同轻链抗体发现平台的分子库的建立过程非常严谨，经由1800+轻链序列比对筛选，25个预建库的验证，12条轻链的抗体表征分析，最终优选2条轻链而建成。该平台筛选出的双抗分子成药性好，且重链遵循自然，多样性高。该平台，搭载的Knob-into-hole技术保障双抗产生过程中的正确配对，消除了双抗产生的错配难题，适用于双抗开发、双靶或双表位ADC、治疗或检测抗体等应用场景。
三优生物共同轻链抗体发现平台以客户需求为中心，配备了库筛选和库嫁接两种类型的服务，不仅适用于单个项目的研发，还可以为客户独家定制子库平台嫁接服务。
相信，三优生物共同轻链抗体发现平台的上线后，将为客户提供重磅助力，攻克双抗药物的研发难点，降低双抗药物可开发性的挑战，极大加速双特异性抗体的研发进程！
关于三优生物
三优生物成立于2015年，是一家国际领先的专注于创新生物药研发和服务的生物高科技企业。公司致力于打通药物研究与开发“端对端”完整的供应链，构建“差异化CRO、整合型CDO、协同型CPO、特色CRS”于一体的4C业务体系，实现“让天下没有难做的创新生物药”的使命。
三优生物建立了20000余平方米、设施设备先进齐全的创新生物药一体化研发实验室。公司打造了居于行业领军水平的“超万亿、一体化、智能化”三大创新药研发技术平台，及以超万亿噬菌体展示抗体库为代表的，涵盖原材料制备、分子发现、分子优化、体内外药效、生产用细胞株构建、上下游工艺开发、临床前研发及产业化开发等50多个核心创新技术子平台。
公司持续推出“创新、卓越、可靠”（三优）的新技术、新产品、新服务和新场景，并和全球1000多家制药公司、药物研发机构、诊断试剂产品公司建立了友好的业务合作关系。
Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched
On June 12th， 2023 local time， Sanyou Biopharmaceuticals Co.， Ltd. officially announced the launch of Sanyou Super Trillion Common Light Chain Antibody Discovery Platform （the platform）.
As one of the nine trillion antibody discovery platforms of Sanyou， the platform features a library capacity of up to 1.12E+12 CFU. For a single target， the platform can generate hundreds of lead antibodies with diverse sequences， which can be further designed into bispecific antibodies with good drug developability， providing a feasible solution for obtaining bispecific antibodies with structures similar to the natural monoclonal antibodies.
Bispecific antibodies are at the forefront of antibody R&D field. Compared with monoclonal antibodies， bispecific antibodies possess one additional antigen binding arm， which brings stronger specificity and better targeting. As of March of 2023， 436 bispecific antibody drug candidates have advanced to clinical trials worldwide， and 10 bispecific antibody drugs had been approved for marketing， with sales of more than 5 billion USD.
The antibody library of the platform was established in a rigorous way. To be specific， 2 common light chains were selected through alignment and screening of 1800+ light chain sequences， validation of 25 proof-of-concept libraries， and antibody characterization and analysis of 12 light chains. The bispecific antibodies generated by this platform exhibit good drug developability， and the heavy chains possess natural antibody properties and high diversity. The platform employs the Knob-into-hole technology to ensure the correct pairing in the process of bispecific antibody formation and eliminate the mismatch. These common light chain antibodies are suitable for multiple application scenarios， such as bispecific antibody development， dual-targeting or bi-paratopic ADC， and therapeutic or detection antibodies.
Following the customer-oriented concept， the platform provides two types of services， i.e.， library screening and library integration， making it not only suitable for the R&D service of individual projects， but also for customers’ integration into their own platforms with the exclusively customized common light chain libraries.
It is believed that the launch of the platform will provide customers with great assistance in overcoming the difficulties in the R&D of bispecific antibody drugs， reducing the challenges in the development of bispecific antibody drugs， and greatly accelerating the R&D of bispecific antibodies.
About Sanyou Bio
Sanyou Biopharmaceuticals Co.， Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain， and has built the 4C business patterns that integrate differentiated CRO， integrated CDO， innovative CPO and characteristic CRS”， to accomplish the mission “to make it easy to discover innovative biological drugs anywhere”.
Sanyou has established an integrated innovative biological drug R&D laboratory of twenty thousand square meters with advanced facilities， and has built three industry-leading innovative technology platforms featured by “super-trillion， integration， and intelligence ， which are comprised of more than 50 sub-platforms with the core innovative super-trillion phage display platform， and supported by platforms of material preparation， antibody discovery， molecule optimization， in vitro and in vivo efficacy， production cell line construction， upstream and downstream process development， preclinical R&D， industrialization development， etc.
Sanyou’s proprietary platform and technology are in continuous optimisation， we launch from time to time upgrades and new version of services and technologies based on principles of innovation， outstanding and reliability. The company has established friendly business collaboration with more than 1000 pharmaceutical companies， drug R&D institutions and diagnostics companies worldwide.
